180 Life Sciences EBITDA
What is the EBITDA of 180 Life Sciences?
The EBITDA of 180 Life Sciences Corp. is -$16.63
What is the definition of EBITDA?
EBITDA is a company’s earnings before interest, taxes, depreciation, and amortization and is an accounting measure calculated using a company’s net earnings, before interest expenses, taxes, depreciation and amortization are subtracted, as a proxy for a company’s current operating profitability.
ttm (trailing twelve months)
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with ebitda similar to 180 Life Sciences
- Siyata Mobile has EBITDA of -$16.69
- Galway Metals has EBITDA of -CAD$16.69
- Galway Metals has EBITDA of -CAD$16.69
- Amicus Therapeutics Inc has EBITDA of -$16.68
- Bionomics has EBITDA of -AUD$16.68
- Redx Pharma Plc has EBITDA of -£16.65
- 180 Life Sciences has EBITDA of -$16.63
- F-Secure Oyj has EBITDA of -€16.57
- Aleafia Health Inc has EBITDA of -CAD$16.57
- Clarus Corp has EBITDA of -$16.56
- Ioneer has EBITDA of -AUD$16.55
- Limeade has EBITDA of -$16.52
- American Resources has EBITDA of -$16.52